Navigation Links
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Date:11/30/2011

m 64

Methods of delivery of cells to the heart 64

Cellular cardiomyoplasty 64

IGF-1 delivery by nanofibers to improve cell therapy for MI 65

Intracoronary infusion of bone marrow-derived cells for AMI 65

Non-invasive delivery of cells to the heart by Morph®guide catheter 65

Transplantation of stem cells for myocardial infarction 66

Transplantation of embryonic stem cells 66

Transplantation of hematopoietic stem cells 66

Transplantation of cord blood stem cells for myocardial infarction 66

Intracoronary infusion of mobilized peripheral blood stem cells 67

Human mesenchymal stem cells for cardiac regeneration 67

Cytokine preconditioning of human fetal liver CD133+ SCs 68

Transplantation of expanded adult SCs derived from the heart 68

Transplantation of endothelial cells 68

Transplantation of genetically modified cells 69

Transplantation of cells secreting vascular endothelial growth factor 69

Transplantation of genetically modified bone marrow stem cells 69

Cell transplantation for congestive heart failure 69

Injection of adult stem cells for congestive heart failure 69

Intracoronary infusion of cardiac stem cells 70

Myoblasts for treatment of congestive heart failure 70

Role of cell therapy in cardiac arrhythmias 70

Atrioventricular conduction block 71

Ventricular tachycardia 71

ESCs for correction of congenital heart defects 72

Cardiac progenitors cells for treatment of heart disease in children 72

Stem cell therapy for peripheral arterial disease 73

Targeted delivery of endothelial progenitor cells labeled with nanoparticles 73

Clinical trials of cell therapy in cardiovascular disease 73

A critical evaluation of cell therapy for heart disease 75

Publications of clinical trials of cell therapy for CVD 76

Future directions for cell therapy of
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
2. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
3. Study Shows Intradigms RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
7. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
8. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
9. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
10. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
11. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... SAN FRANCISCO, Calif., May 16, 2012  Rigel Pharmaceuticals, Inc., ... franchise by focusing on two innovative, comprehensive treatment alternatives ... an inhaled SYK inhibitor, will be entering a Phase ... moderate asthmatic patients. The other, R256, an inhaled IL13 ...
... May 15, 2012   OphthaliX (OTCBB: OPLI) today ... ended March 31, 2012. OphthaliX is an advanced clinical-stage ... treatment of ophthalmic disorders.  Our drug, CF101 (known generically ... indications: dry eye syndrome; glaucoma and uveitis. We are ...
Cached Medicine Technology:Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 2Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 3Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 4OphthaliX Reports First Quarter 2012 Financial Results 2OphthaliX Reports First Quarter 2012 Financial Results 3
(Date:11/28/2014)... (PRWEB) November 28, 2014 Earlier ... reported during the hugely popular, 2014 MTV Video ... organization Truth launched ground-breaking celebrity centered television advertisements ... MTV viewership figures were estimated by Entertainment ... ads placed the spotlight on celebrities photographed by ...
(Date:11/28/2014)... New York (PRWEB) November 28, 2014 ... http://www.consumerinjurylawyers.com/stryker-rejuvenate/stryker-hip-lawsuits/ ) have now been filed in a ... recalled metal implants, Bernstein Liebhard LLP reports. ... in Bergen County Superior Court reflects the filing ... II modular-neck hip stems, which were voluntarily recalled ...
(Date:11/28/2014)... a leader in the wig industry, has announced a great ... promotion features: , > 400 pieces of FOUR ... (no coupon code needed), > 10% off for ... $49 , Visit http://www.uniwigs.com for more details , The ... 1st and the first 100 shoppers each day will receive our ...
(Date:11/28/2014)... November 28, 2014 Patten Pecans, based ... grown. With those passions driving them, they've added a ... Having tried other pecans oils, they've found this ... to be exceptionally flavorful, retaining the buttery pecan notes ... nutritional benefits found in pecans nuts is ...
(Date:11/28/2014)... 28, 2014 An inventor from Flint, Mich., ... day. "I got this idea while lying in a hospital ... he said. , The Bed Buddy provides a more ergonomic ... the bathroom. It eliminates the need to leave the bed, ... and dignity. Easy to use and producible in design variations, ...
Breaking Medicine News(10 mins):Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3Health News:Pre-X'mas Crazy Sale Starts from $0 at UniWigs.com 2Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
... Carson M.D., professor of medicine and director of the Rebecca ... California, San Diego (UCSD) has identified a potent new anti-cancer ... South Pacific. The properties of somocystinamide A (ScA) are ... Proceedings of the National Academy of Science the week of ...
... A University of Alberta study recommends that workers on pig ... a child on a communal farm in Canada was diagnosed ... made a full recovery, health researchers were concerned because of ... multi-family community, who, fortunately, all demonstrated mild or no apparent ...
... $1 million, Five-year Grant, from New York State Department ... Becomes Lead,Poisoned, NEW YORK, Feb. 11 The ... at Montefiore,(CHAM) has been named one of three State ... regional healthcare delivery for children and,pregnant women with elevated ...
... lead to less controversial method of treating diseases , , ... they,ve reprogrammed human skin cells into ones with the ... that could aid in treating many diseases while sidestepping ... to become every cell type found in the human ...
... Inc.,(Nasdaq: NXXI ), the developer and marketer ... Iceland Health(R) brands that,help consumers manage blood sugar ... joint pain, today announced financial,results for the second ... 2007., The Company reported a 43% increase ...
... Feb. 11 Lincare Holdings,Inc. (Nasdaq: LNCR ), ... delivered to patients in the home, today announced,financial results ... 2007., For the quarter ended December 31, 2007, ... $368.1 million for the fourth quarter of,2006. The Company ...
Cached Medicine News:Health News:UCSD research team identifies novel anticancer drug from the sea 2Health News:Swine flu monitoring needed for farm workers, study says 2Health News:Montefiore Lead Poisoning Prevention ProgramNamed One of Three State Regional Resource Centers 2Health News:Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 2Health News:Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 3Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 2Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 3Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 4Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 5Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 6Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 7Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 2Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 3Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 4Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 5Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 6Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 7
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Duraloc acetabular cup system....
... acetabular cup system has been designed to ... tri-spiked and cluster hole configurations. The objective ... micromotion on three primary modes: Tilt, migration ... features result in initial and long-term fixation. ...
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
Medicine Products: